Cell Therapy News/Articles, page-820

At the very end of the article is this;

The challenge, says Dr Saunders? “At the moment it costs half a million dollars per patient."

This is the next step. Bringing down the cost of immunotherapy, while also continuing clinical trials to see what other cancers it will work on.

And the opening sentence of the Cartherics Pty Ltd CRC-P grant description is;

This CRC-P will develop “off-the-shelf” immunotherapy products for cancer.

Off the shelf cellular medicines, now which company do we know that is well down the start of that track, has some real world production expertise.

"The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies."

"Mesoblast will make an in-kind contribution of its allogeneic cell platform technology as well as providing scientific expertise."

From https://www.asx.com.au/asxpdf/20180529/pdf/43vcrvpgkyqvyy.pdf

Also I would be interested to find out if 2019s Project 2 from Cartherics has begun to show signs of success, a potential move on from CAR-T. Additionally would this still use Mesoblast expertise in some way, considering the mention of "off the shelf" in the project name?

Project 2:Re-engineering the function of natural killer cell receptors via CRISPR/Cas9: a new approach for ‘off-the-shelf’ immunotherapy.

Supervisors: Professor Richard Boyd
Co-supervisor: Dr Roland Shu, Dr Vera Evtimov, Dr Nicholas Boyd

Download